Bottom-up physiologically based pharmacokinetic modelling for predicting the human pharmacokinetic profiles of the ester prodrug MGS0274 and its active metabolite MGS0008, a metabotropic glutamate 2/3 receptor agonist

References

• Bi Y, Scialis RJ, Lazzaro S, Mathialagan S, Kimoto E, Keefer J, Zhang H, Vildhede AM, Costales C, Rodrigues AD, et al. 2017. Reliable rate measurements for active and passive hepatic uptake using plated human hepatocytes. AAPS J. 19(3):787–796.
   PubMed Web of Science ®Google Scholar
• Blouin A, Bolender RP, Weibel ER. 1977. Distribution of organelles and membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma. A stereological study. J Cell Biol. 72(2):441–455.
   PubMed Web of Science ®Google Scholar
• Clarke SE. 1998. In vitro assessment of human cytochrome P450. Xenobiotica. 28(12):1167–1202.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res. 10(7):1093–1095.
   PubMed Web of Science ®Google Scholar
• De Bruyn T, Ufuk A, Cantrill C, Kosa RE, Bi Y, Niosi M, Modi S, Rodrigues AD, Tremaine LM, Varma MVS, et al. 2018. Predicting human clearance of organic anion transporting polypeptide substrates using cynomolgus monkey: in vitro-in vivo scaling of hepatic uptake clearance. Drug Metab Dispos. 46(7):989–1000.
   PubMed Web of Science ®Google Scholar
• Di L. 2019. The impact of carboxylesterases in drug metabolism and pharmacokinetics. Curr Drug Metab. 20(2):91–102.
   PubMed Web of Science ®Google Scholar
• Fukami T, Yokoi T. 2012. The emerging role of human esterases. Drug Metab Pharmacokinet. 27(5):466–477.
   PubMed Web of Science ®Google Scholar
• Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, et al. 2009. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol. 49(5):513–533.
   PubMed Web of Science ®Google Scholar
• Hu Z, Edginton AN, Laizure SC, Parker RB. 2014. Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition. Clin Pharmacokinet. 53(9):825–836.
   PubMed Web of Science ®Google Scholar
• Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, Snoeys J, Upreti VV, Zheng M, Hall SD. 2015. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 97(3):247–262.
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Ochi M, Iwata K, Fukasawa M, Yamaguchi J. 2019. Preclinical disposition of MGS0274 besylate, a prodrug of a potent group II metabotropic glutamate receptor agonist MGS0008 for the treatment of schizophrenia. Pharmacol Res Perspect. 7(5):e00520.
   PubMed Web of Science ®Google Scholar
• Li R, Bi Y, Lai Y, Sugano K, Steyn SJ, Trapa PE, Di L. 2014. Permeability comparison between hepatocyte and low efflux MDCKII cell monolayer. AAPS J. 16(4):802–809.
   PubMed Web of Science ®Google Scholar
• Lombardo F, Waters NJ, Argikar UA, Dennehy MK, Zhan J, Gunduz M, Harriman SP, Berellini G, Rajlic IL, Obach RS. 2013. Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 1: volume of distribution at steady state. J Clin Pharmacol. 53(2):167–177.
   PubMed Web of Science ®Google Scholar
• Lukacova V, Goelzer P, Reddy M, Greig G, Reigner B, Parrott N. 2016. A physiologically based pharmacokinetic model for ganciclovir and its prodrug valganciclovir in adults and children. AAPS J. 18(6):1453–1463.
   PubMed Web of Science ®Google Scholar
• Malmborg J, Ploeger BA. 2013. Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico-in vivo extrapolation and physiologically-based pharmacokinetic modeling approach. J Pharmacol Toxicol Methods. 67(3):203–213.
   PubMed Web of Science ®Google Scholar
• Masaoka Y, Tanaka Y, Kataoka M, Sakuma S, Yamashita S. 2006. Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur J Pharm Sci. 29(3-4):240–250.
   PubMed Web of Science ®Google Scholar
• Nishimuta H, Houston JB, Galetin A. 2014. Hepatic, intestinal, renal, and plasma hydrolysis of prodrugs in human, cynomolgus monkey, dog, and rat: implications for in vitro-in vivo extrapolation of clearance of prodrugs. Drug Metab Dispos. 42(9):1522–1531.
   PubMed Web of Science ®Google Scholar
• Oda S, Fukami T, Yokoi T, Nakajima M. 2015. A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. Drug Metab Pharmacokinet. 30(1):30–51.
   PubMed Web of Science ®Google Scholar
• Parrott N, Davies B, Hoffmann G, Koerner A, Lave T, Prinssen E, Theogaraj E, Singer T. 2011. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin Pharmacokinet. 50(9):613–623.
   PubMed Web of Science ®Google Scholar
• Rautio J, Meanwell NA, Di L, Hageman MJ. 2018. The expanding role of prodrugs in contemporary drug design and development. Nat Rev Drug Discov. 17(8):559–587.
   PubMed Web of Science ®Google Scholar
• Rodgers T, Rowland M. 2007. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res. 24(5):918–933.
   PubMed Web of Science ®Google Scholar
• Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. 2015. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug Metab Dispos. 43(11):1823–1837.
   PubMed Web of Science ®Google Scholar
• Trapa PE, Beaumont K, Atkinson K, Eng H, King-Ahmad A, Scott DO, Maurer TS, Di L. 2017. In vitro-in vivo extrapolation of intestinal availability for carboxylesterase substrates using portal vein-cannulated monkey. J Pharm Sci. 106(3):898–905.
   PubMed Web of Science ®Google Scholar
• Urabe H, Miyakoshi N, Ohtake N, Nozoe A, Ochi M, Fukasawa M, Kinoshita K, Yamaguchi J-I, Marumo T, Hikichi H, et al. 2020. Discovery of MGS0274, an ester prodrug of a metabotropic glutamate receptor 2/3 agonist with improved oral bioavailability. Eur J Med Chem. 203:112521.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Marcy B, Kinoshita K, Fukasawa M, Hikichi H, Chaki S, Okuyama S, Gevorkyan H, Yoshida S. 2020. Safety and pharmacokinetic profiles of MGS0274 besylate (TS-134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects. Br J Clin Pharmacol. 86(11):2286–2301.
   PubMed Web of Science ®Google Scholar
• Williams ET, Bacon JA, Bender DM, Lowinger JJ, Guo W-K, Ehsani ME, Wang X, Wang H, Qian Y-W, Ruterbories KJ, et al. 2011. Characterization of the expression and activity of carboxylesterases 1 and 2 from the beagle dog, cynomolgus monkey, and human. Drug Metab Dispos. 39(12):2305–2313.
   PubMed Web of Science ®Google Scholar
• Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. 2007. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab. 8(7):676–684.
   PubMed Web of Science ®Google Scholar